Skip to main content
. 2011 Oct 20;12:231. doi: 10.1186/1745-6215-12-231

Table 2.

Data Collection Measures and Instruments

Measure Data Collected Method
Primary Outcome Hemoglobin A1c Blood specimens will be obtained at baseline, 3-, and 6-months visits.

Secondary Outcomes Blood Pressure Blood pressure readings will be obtained at baseline, 3-, and 6-months visits.

Quality of life Quality of life will be measured by the SF-12 [31], which is a valid and reliable instrument to measure functional status.


Process Measures Information This will be measured by the 24-item Diabetes Knowledge Questionnaire (DKQ) [32]

Motivation This will be measured with the 12-item Diabetes Fatalism Scales (DFS) [33].

Self-Efficacy This will be measured by the perceived diabetes self-management scale (PDSMS) [34].

Behavioral Skills This will be assessed with the Summary of Diabetes Self-Care Activities (SDSCA) scale [35].

Medication Adherence This will be measured with the new 8-item self-report Morisky Medication Adherence Scale (MMAS) [36].


Self-report measures Demographics Previously validated items from the 2002 National Health Interview Survey [37] will be used to capture age, gender, race/ethnicity, marital status, household income, and health insurance.

Social support The Medical Outcomes Study (MOS) Social Support Survey [38] will be used to measure social support.

Health Literacy The abbreviated version of the Test of Functional Health Literacy in Adults (S-TOFHLA) [39] is designed to rapidly screen patients for potential health literacy problems.

Depression The PHQ-9 is a brief questionnaire that scores each of the 9 DSM-IV criteria for depression [40].

Medical Comorbidity The patient's history of medical comorbidity will be documented using a standardized and validated questionnaire [41].

Service Delivery Perceptions This will be assessed with 5 items that have been previously validated in mental health studies. The items were slightly modified to be relevant to diabetes.

Treatment Credibility To assess for differences in outcome expectancy, a modified treatment credibility scale developed by Borkovec and Nau (1972) will be used [42].

Resource Utilization & Cost The perspective of cost will be that of the payer. Previously validated questions on resource utilization will be administered as a part of the baseline, 3-, and 6-month visits.